IP Library Granted Patent US 8,470,874
Granted Patent B2
US 8,470,874 · App. 10/561,756 · Granted Jun 25, 2013

Pharmaceutical compositions comprising cannabichromene type compounds

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,470,874
App. No.
10/561,756
Granted
Jun 25, 2013
Kind
B2
Abstract

The invention relates to the use of cannabichromene type compounds and derivatives thereof in the treatment of mood disorders.

Claims (9)

1. A method for treating depression in a human patient, which comprises administering to a patient in need thereof a therapeutically effective amount of cannabichromene (CBC)

wherein the CBC is substantially pure or is an extract from a cannabis plant that contains greater than or equal to 30% CBC of the total cannabinoid content, and wherein the CBC is administered as a unit dosage form that comprises CBC in an amount of 0.1 mg to 1000 mg.

2. The method according to claim 1 wherein the CBC is present in an extract of at least one cannabis plant.

3. The method according to claim 1 , wherein the CBC is administered nasally, sublingually, buccally, topically, orally, rectally, intravenously, intra-peritoneally, intra-muscularly, subcutaneously, transdermally, intra-vaginally, intra-urethrally, by nebuliser, as inhaled vapour or by installation directly into the bladder.

4. The method according to claim 2 , wherein the extract comprises substantially all the naturally occurring cannabinoids in said at least one cannabis plant.

5. The method according to claim 2 , wherein the extract is enriched for CBC.

6. The method according to claim 1 , wherein the CBC is administered in an isolated and substantially pure form.

7. The method according to claim 1 , wherein the CBC is administered together with one or more pharmaceutically acceptable diluents, excipients or carriers.

8. The method according to claim 1 , wherein the CBC is not administered as inhaled vapour.

Assignments (2)
SECURITY AGREEMENT Recorded Jul 22, 2021
From: GW PHARMA LIMITED; GW RESEARCH LIMITED
To: U.S. BANK NATIONAL ASSOCIATION
Reel/Frame 056958/0493 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 14, 2007
From: MUSTY, RICHARD; DEYO, RICHARD
To: GW PHARMA LIMITED
Reel/Frame 020111/0006 →